share_log

Avenue Therapeutics | 8-K: Current report

SEC announcement ·  Feb 24 05:25
Summary by Futu AI
Avenue Therapeutics, Inc. has officially increased its authorized shares from 75 million to 200 million, as detailed in a recent Form 8-K filing with the SEC. The stockholder consent for this increase was obtained on January 9, 2024, and the Certificate of Amendment was filed with the Delaware Secretary of State on February 20, 2024. This amendment to the company's Third Amended and Restated Certificate of Incorporation is documented in exhibit 3.1 of the report. The company's common stock is traded under the symbol ATXI on the Nasdaq Capital Market.
Avenue Therapeutics, Inc. has officially increased its authorized shares from 75 million to 200 million, as detailed in a recent Form 8-K filing with the SEC. The stockholder consent for this increase was obtained on January 9, 2024, and the Certificate of Amendment was filed with the Delaware Secretary of State on February 20, 2024. This amendment to the company's Third Amended and Restated Certificate of Incorporation is documented in exhibit 3.1 of the report. The company's common stock is traded under the symbol ATXI on the Nasdaq Capital Market.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.